cGVHD characteristics based on the aGVHD response
| . | No aGVHD (n = 78) . | SS aGVHD (n = 31) . | SD aGVHD (n = 48) . | Steroid-refractory aGVHD (n = 41) . | Total (n = 198) . |
|---|---|---|---|---|---|
| cGVHD onset | |||||
| De novo | 78 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 77 (39%) |
| Quiescent | 0 (0%) | 25 (81%) | 29 (60%) | 25 (62%) | 79 (40%) |
| Progressive | 0 (0%) | 6 (19%) | 19 (40%) | 15 (38%) | 41 (21%) |
| cGVHD type | |||||
| Classic | 54 (69%) | 17 (55%) | 31 (66%) | 25 (62%) | 127 (65%) |
| Overlap | 24 (31%) | 14 (45%) | 16 (34%) | 15 (38%) | 69 (35%) |
| cGVHD severity | |||||
| Mild | 12 (15%) | 6 (19%) | 11 (23%) | 6 (15%) | 35 (18%) |
| Moderate | 50 (64%) | 18 (58%) | 27 (57%) | 22 (55%) | 117 (60%) |
| Severe | 16 (21%) | 7 (23%) | 9 (19%) | 12 (30%) | 44 (22%) |
| . | No aGVHD (n = 78) . | SS aGVHD (n = 31) . | SD aGVHD (n = 48) . | Steroid-refractory aGVHD (n = 41) . | Total (n = 198) . |
|---|---|---|---|---|---|
| cGVHD onset | |||||
| De novo | 78 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 77 (39%) |
| Quiescent | 0 (0%) | 25 (81%) | 29 (60%) | 25 (62%) | 79 (40%) |
| Progressive | 0 (0%) | 6 (19%) | 19 (40%) | 15 (38%) | 41 (21%) |
| cGVHD type | |||||
| Classic | 54 (69%) | 17 (55%) | 31 (66%) | 25 (62%) | 127 (65%) |
| Overlap | 24 (31%) | 14 (45%) | 16 (34%) | 15 (38%) | 69 (35%) |
| cGVHD severity | |||||
| Mild | 12 (15%) | 6 (19%) | 11 (23%) | 6 (15%) | 35 (18%) |
| Moderate | 50 (64%) | 18 (58%) | 27 (57%) | 22 (55%) | 117 (60%) |
| Severe | 16 (21%) | 7 (23%) | 9 (19%) | 12 (30%) | 44 (22%) |
SD has 1 unknown type and severity. Steroid refractory has 1 unknown onset, type, and severity.